Department of General surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, Liaoning Province 110032, China.
Anesthesia Department, The Fourth Affiliated Hospital, China Medical University, Shenyang, Liaoning Province 110032, China.
Biomed Pharmacother. 2024 Aug;177:116925. doi: 10.1016/j.biopha.2024.116925. Epub 2024 Jun 14.
Macrophages are central to the immune system and are found in nearly all tissues. Recently, the development of therapies based on macrophages has attracted significant interest. These therapies utilize macrophages' key roles in immunity, their ability to navigate biological barriers, and their tendency to accumulate in tumors. This review explores the advancement of macrophage-based treatments. We discuss the bioengineering of macrophages for improved anti-tumor effects, the use of CAR macrophage therapy for targeting cancer cells, and macrophages as vehicles for therapeutic delivery. Additionally, we examine engineered macrophage products, like extracellular vesicles and membrane-coated nanoparticles, for their potential in precise and less toxic tumor therapy. Challenges in moving these therapies from research to clinical practice are also highlighted. The aim is to succinctly summarize the current status, challenges, and future directions of engineered macrophages in cancer therapy.
巨噬细胞是免疫系统的核心，几乎存在于所有组织中。最近，基于巨噬细胞的治疗方法的发展引起了极大的关注。这些治疗方法利用了巨噬细胞在免疫中的关键作用、它们穿越生物屏障的能力以及它们在肿瘤中积累的倾向。本综述探讨了基于巨噬细胞的治疗方法的进展。我们讨论了为提高抗肿瘤效果而对巨噬细胞进行的生物工程改造，利用 CAR 巨噬细胞疗法靶向癌细胞，以及巨噬细胞作为治疗药物载体的应用。此外，我们还研究了工程化巨噬细胞产品，如细胞外囊泡和膜包覆的纳米颗粒，以评估它们在精确和低毒肿瘤治疗方面的潜力。还强调了将这些疗法从研究推向临床实践所面临的挑战。目的是简洁地总结工程化巨噬细胞在癌症治疗中的现状、挑战和未来方向。
